Anders U.
- Country
- Sweden
- Department
- Urologic oncology
Research Overview
- A Phase 3 Study of MK-2870 Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced or Metastatic Urothelial Carcinoma
- Outcome-Adaptive Randomized Multi-Arm Study of Radium-223 Dichloride, Abiraterone Acetate, and Drug Combinations in Metastatic Prostate Cancer Patients
- C5731001 - An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
Data & Insights
Has run more than one trial at 75 of 202 partner sites.
Specializations
Urologic Oncology
Anders Ullen’s clinical research includes a strong focus on prostate cancer, metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and localized high-risk prostate adenocarcinoma. His work also extends to urothelial carcinoma and muscle-invasive bladder cancer, with interest in advanced and recurrent disease settings.
- Prostate cancer
- Metastatic castration-resistant prostate cancer
- Urothelial carcinoma
- Muscle-invasive bladder cancer
His portfolio reflects ongoing involvement in therapeutic strategies for advanced genitourinary malignancies, including biomarker-directed approaches and treatment optimization in renal cell carcinoma and bladder cancer.
Renal and Transplant Medicine
His research landscape includes chronic kidney disease, end-stage kidney disease, IgA nephropathy, focal segmental glomerulosclerosis, and kidney transplant rejection. He is also involved in studies addressing proteinuria and immune-mediated renal injury.
- Chronic kidney disease
- IgA nephropathy
- Kidney transplant rejection
- Proteinuria
Additional interests include renal transplantation, sensitized transplant populations, and therapies aimed at preserving renal function in progressive kidney disease.
Hematologic Malignancies
Anders Ullen is active in trials spanning multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and acute myeloid leukemia. His clinical interests also include myelodysplastic syndrome and other relapsed or refractory blood cancers.
- Multiple myeloma
- Chronic lymphocytic leukemia
- Diffuse large B-cell lymphoma
- Acute myeloid leukemia
This area of work covers both newly diagnosed and advanced hematologic disease, with attention to targeted and immune-based treatment options.
Solid Tumors and Surgical Oncology
His trial activity also covers breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and gastric cancer. He has research involvement in advanced and metastatic solid tumors, including non-small cell lung cancer, melanoma, and endometrial cancer.
- Breast cancer
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
His portfolio includes perioperative and post-surgical oncology topics, as well as treatment approaches for locally advanced and metastatic disease.
Immune-Mediated and Systemic Disease
Anders Ullen’s research interests extend to systemic lupus erythematosus, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and multiple sclerosis. He is also involved in studies of asthma, psoriasis, and other immune-driven inflammatory conditions.
- Systemic lupus erythematosus
- Crohn’s disease
- Rheumatoid arthritis
- Multiple sclerosis
These activities reflect therapeutic interest in immune modulation across chronic inflammatory and autoimmune disorders, alongside oncology-focused research.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.